Target type: molecularfunction
Binding to a low-density lipoprotein particle, a lipoprotein particle that is rich in cholesterol esters and low in triglycerides, is typically composed of APOB100 and APOE, and has a density of 1.02-1.06 g/ml and a diameter of between 20-25 nm. [GOC:mah]
Low-density lipoprotein (LDL) particles, also known as "bad cholesterol", are crucial for delivering cholesterol to cells throughout the body. The molecular function of LDL particle binding involves a complex interplay of proteins and lipids that facilitate this delivery process.
1. **Ligand Recognition:** LDL particles possess a unique structure with a core of cholesterol esters surrounded by a monolayer of phospholipids and apolipoprotein B-100 (apoB-100). ApoB-100 serves as the primary ligand that binds to LDL receptors (LDLR) on the surface of cells. The interaction between apoB-100 and LDLR is highly specific and mediated by a series of amino acid residues on both molecules.
2. **Receptor-mediated Endocytosis:** Once the LDL particle binds to the LDLR, the complex is internalized into the cell via endocytosis. This process is initiated by the clustering of LDLRs and the formation of clathrin-coated pits, which invaginate and pinch off from the plasma membrane.
3. **Uncoating and Trafficking:** The clathrin-coated vesicle containing the LDL particle undergoes uncoating, releasing the LDL into an early endosome. The endosome then acidifies, causing a conformational change in the LDLR, which weakens its hold on the LDL particle.
4. **Lysosomal Degradation:** The LDL particle is transported to a late endosome, which eventually fuses with a lysosome. The acidic environment and the presence of lysosomal hydrolases within the lysosome break down the LDL particle, releasing free cholesterol into the cytoplasm.
5. **Cholesterol Utilization:** The cholesterol liberated from LDL particles is used by the cell for various purposes, including the synthesis of hormones, cell membranes, and bile acids.
6. **LDLR Recycling:** The LDLR, after releasing the LDL particle, is recycled back to the cell surface, ready to bind another LDL particle. This recycling process ensures continuous uptake of LDL cholesterol.
In summary, the molecular function of LDL particle binding involves a series of tightly regulated events, from ligand recognition and receptor-mediated endocytosis to lysosomal degradation and cholesterol utilization. This process is crucial for maintaining cholesterol homeostasis in the body and preventing the development of cardiovascular disease.'
"
Protein | Definition | Taxonomy |
---|---|---|
Scavenger receptor class B member 1 | A scavenger receptor class B member 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8WTV0] | Homo sapiens (human) |
Proprotein convertase subtilisin/kexin type 9 | A proprotein convertase subtilisin/kexin type 9 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8NBP7] | Homo sapiens (human) |
Hepatic triacylglycerol lipase | A hepatic triacylglycerol lipase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P11150] | Homo sapiens (human) |
Low-density lipoprotein receptor | A low-density lipoprotein receptor that is encoded in the genome of human. [PRO:DNx, UniProtKB:P01130] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
rimcazole | rimcazole: RN given refers to (cis)-isomer; structure given in first source | carbazoles | |
s 1033 | (trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide | anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor | |
orlistat | orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug. Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity. | beta-lactone; carboxylic ester; formamides; L-leucine derivative | anti-obesity agent; bacterial metabolite; EC 2.3.1.85 (fatty acid synthase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor |
xen445 | |||
PF-06446846 | PF-06446846 : A triazolopyridine that is 3H-[1,2,3]triazolo[4,5-b]pyridine substituted by a 4-{(3-chloropyridin-2-yl)[(3R)-piperidin-3-yl]carbamoyl}phenyl group at position 3. It is a potent inhibitor of PCSK9. PF-06446846: inhibits translation of PCSK9 ;structure in first source | benzamides; monochloropyridine; piperidines; tertiary carboxamide; triazolopyridine | antilipemic drug; EC 3.4.21.61 (kexin) inhibitor |